ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
uniQure NV

uniQure NV (QURE)

7.80
-0.67
(-7.91%)
Closed July 19 3:00PM
7.91
0.11
(1.41%)
After Hours: 6:59PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
7.91
Bid
8.05
Ask
8.08
Volume
2,734,621
7.65 Day's Range 8.61
3.73 52 Week Range 11.35
Market Cap
Previous Close
8.47
Open
8.47
Last Trade Time
Financial Volume
US$ 22,060,475
VWAP
8.0671
Average Volume (3m)
2,935,667
Shares Outstanding
48,549,437
Dividend Yield
-
PE Ratio
-1.22
Earnings Per Share (EPS)
-6.35
Revenue
21.9M
Net Profit
-308.48M

About uniQure NV

uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipel... uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Amsterdam, North Holland, Nld
Founded
1970
uniQure NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker QURE. The last closing price for uniQure NV was US$8.47. Over the last year, uniQure NV shares have traded in a share price range of US$ 3.73 to US$ 11.35.

uniQure NV currently has 48,549,437 shares outstanding. The market capitalization of uniQure NV is US$411.21 million. uniQure NV has a price to earnings ratio (PE ratio) of -1.22.

uniQure NV (QURE) Options Flow Summary

Overall Flow

Bullish

Net Premium

344k

Calls / Puts

200.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

QURE Latest News

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the...

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA PR Newswire BOSTON and INDIANAPOLIS, July 1, 2024 Strategic acquisition will enable Genezen to...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.52-24.161073825510.4310.87.6551942508.88891166CS
43.475.38802660754.5111.353.7376526898.43050735CS
123.4978.95927601814.4211.353.7329356677.97396224CS
262.1136.37931034485.811.353.7318677327.25293912CS
52-2.71-25.517890772110.6211.353.7315186697.24990837CS
156-18.43-69.969627942326.3438.83.7393692913.62960979CS
260-64.11-89.01693973972.0276.853.7375352522.41125972CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TNZTenaz Energy Corp
$ 5.73
(56.13%)
1.11M
VRTSGamelancer Media Corp
$ 0.02
(33.33%)
108.1k
NCFNorthcliff Resources Ltd
$ 0.025
(25.00%)
1.75k
IVQ.UInvesque Inc
US$ 0.15
(15.38%)
5k
AMMAlmaden Minerals Ltd New
$ 0.08
(14.29%)
70k
HWOHigh Arctic Energy Services Inc
$ 0.84
(-45.45%)
70.17k
AVCNAvicanna Inc
$ 0.365
(-17.05%)
166.2k
BCTBriaCell Therapeutics Corp
$ 1.05
(-16.00%)
145.63k
PNC.APostmedia Network Canada Corp
$ 1.33
(-13.64%)
801
VGCXVictoria Gold Corp
$ 0.67
(-12.99%)
1.13M
CNQCanadian Natural Resources Ltd
$ 48.92
(0.18%)
14.63M
RYRoyal Bank of Canada
$ 153.71
(0.25%)
8.73M
ENBEnbridge Inc
$ 49.74
(0.32%)
8.35M
ABXBarrick Gold Corporation
$ 25.41
(-1.70%)
7.06M
SUSuncor Energy Inc
$ 53.25
(0.15%)
6.74M

QURE Discussion

View Posts
retireat40 retireat40 19 hours ago
Agree until more news is released.
👍️0
Romiman Romiman 1 day ago
Got in at 5.85, I’ll be out tomorrow, this one is done.
👍️0
retireat40 retireat40 1 day ago
WTH? New LOD every time I check.
👍️0
retireat40 retireat40 3 days ago
Nope
👍️0
retireat40 retireat40 3 days ago
Turd city…
👍️0
retireat40 retireat40 4 days ago
Even less volume today than last Friday.
👍️0
retireat40 retireat40 4 days ago
Agree. Odd that it trades in the 8’s
👍️0
PonkenPlonken PonkenPlonken 5 days ago
I became an investor the second i saw the results but i also traded around my position. Ergo I am riding a free ticket now.
Company has 11$ per share in cash and the science is probably worth 2-4bn $.
👍️0
retireat40 retireat40 6 days ago
Bull or bear?
👍️0
retireat40 retireat40 6 days ago
Looked like crapola today
👍️0
tbonaces80 tbonaces80 7 days ago
Flagg forming
👍️0
PonkenPlonken PonkenPlonken 7 days ago
institutions use liquidity = take a seat and watch the scenario unfold.
👍️0
retireat40 retireat40 1 week ago
We’ll see. 80% drop in volume today.
👍️0
TechandBio TechandBio 1 week ago
UniQure Interesting move here solid pipeline added a few calls for early July for fun.
Keep an eye o Ice Cure killing cancer by cryoblation ICCM one of the most undervalued stocks.
$QURE
👍️0
tbonaces80 tbonaces80 1 week ago
Great chart. Shooting for a rip beteen $12.41-$16.75.
👍️0
PonkenPlonken PonkenPlonken 1 week ago
traders are too busy trying to make $ in silly names. Every few months there is a play like this.... that doesnt require much thinking-- only spotting it and letting the big guys do the lifting.
👍️0
PonkenPlonken PonkenPlonken 1 week ago
Listen to Victor Sung on the recent call. You dont need to be in the know to hear he hasnt seen anything similar

https://edge.media-server.com/mmc/p/m4opdukf
👍️0
Monksdream Monksdream 3 months ago
QURE under $5
👍️0
Liam859 Liam859 4 months ago
$QURE $5.14 buy it up
👍️0
MiamiGent MiamiGent 2 years ago
QURE

$26.36 +3.36 (+14.61%)
As of Nov-23-20224:00:00 PM ET

https://stockcharts.com/h-sc/ui?s=QURE

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
BENZINGA 8:12 AM ET Nov-23-2022

UniQure N.V.'s (NASDAQ:QURE) partner CSL Limited (OTC:CSLLY) has received FDA approval for Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B.
CSL licensed the exclusive global rights to Hemgenix from uniQure in May 2021.
UniQure has received about $500 million so far from CSL and will also be eligible to get up to an additional $1.5 billion in commercial milestone payments and royalties.
Cowen analyst Joseph Thome said that Hemgenix's price of $3.5 million is higher than the brokerage's estimated $1.9 million, but its consultants have been optimistic about the therapy's uptake, Reuters reported.
Results from the pivotal HOPE-B trial support the FDA approval, the largest gene therapy trial in hemophilia B.
Results from the study demonstrated that Hemgenix allowed patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion.
Seven to 18 months post-infusion, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54% compared to the six-month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9).
In addition, 94% of patients treated with Hemgenix discontinued prophylaxis and remained free of previous continuous routine prophylaxis therapy.
The FDA has already cleared two gene therapies, Zynteglo and Skysona, from Bluebird bio Inc (NASDAQ: BLUE) in August and September, respectively.
👍️0
Glider549 Glider549 2 years ago
Whoops!
👍️0
ralphey ralphey 2 years ago
Insiders selling big time while biopharmcatalyst site tries to pump - noit a good sign
👍️0
Sunnycupid Sunnycupid 7 years ago
Profit taking time .. Good time to short this .. I want to be in for a short
👍️0
Thoro Thoro 7 years ago
QURE $9.15 high today, nice.
👍️0
Thoro Thoro 7 years ago
This thing is pretty volatile lately.
👍️0
Thoro Thoro 7 years ago
QURE Looked great hitting $9.00 today
👍️0
Thoro Thoro 7 years ago
QURE General Information

http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=QURE.O
👍️0
Thoro Thoro 7 years ago
Uniqure NV (QURE) Money Flow Index Nearing Key Level

http://tuckermantimes.com/uniqure-nv-qure-money-flow-index-nearing-key-level/247578/

👍️0
Thoro Thoro 7 years ago
Erratic Trading Showing Unusual Volume in Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) and uniQure N.V. (NASDAQ:QURE)

https://www.concordregister.com/erratic-trading-showing-unusual-volume-in-shares-of-concert-pharmaceuticals-inc-nasdaqcnce-and-uniqure-n-v-nasdaqqure/

👍️0
Thoro Thoro 7 years ago
uniQure N.V. NASDAQ:QURE Sees High Volatility in Session

https://aikenadvocate.com/uniqure-n-v-nasdaqqure-sees-high-volatility-in-session/290264/
👍️0
Thoro Thoro 7 years ago
uniQure N.V. (QURE) PT Set at $13.00 by Chardan Capital

https://weekherald.com/2017/07/24/uniqure-n-v-qure-pt-set-at-13-00-by-chardan-capital.html
👍️0
Rogerthat1 Rogerthat1 7 years ago
This dog has always been a turd. Why did it run last couple days? Already see signs of rollover on today's intraday imo. $QURE
👍️0
Dutchdaan Dutchdaan 7 years ago
buying here
👍️0
Panzer Panzer 8 years ago
Lost all patience in this pos
👍️0
redsox17 redsox17 8 years ago
Patient is a virtue.
If you know what you are doing it pays off.
👍️0
jaytea jaytea 8 years ago
That's why it's down another 3%
👍️0
redsox17 redsox17 8 years ago
Trust me they are. They just don't want you to think that way.
👍️0
jaytea jaytea 8 years ago
The market does not seem to be overly impressed.
👍️0
redsox17 redsox17 8 years ago
Great news out
👍️0
redsox17 redsox17 8 years ago
Great newsGo QURE

uniQure N.V. (NASDAQ:QURE) announced the completion of a company-wide strateghttp://www.benchmarkmonitor.com/2016/11/17/uniqure-n-v-nasdaqqure-announced-the-completion-of-a-company-wide-strategic-review/ic review


uniQure N.V. (NASDAQ:QURE), announced the completion of a company-wide strategic review aimed at refocusing its pipeline, consolidating its manufacturing and enhancing overall execution to drive shareholder value. As a result of this initiative, the Company will prioritize programs in hemophilia B, Huntington’s disease and those associated with its landmark collaboration with Bristol-Myers Squib (BMS) in cardiovascular disease.

uniQure N.V. (NASDAQ:QURE), a Healthcare sector firm, traded 495604 shares in last trading session with closing price of $7.04 per share. Company gross margin stands at 94.90% whereas its return on investment (ROI) is -49.30%. Stock value has moved between $6.64 – 22.71 in last one year. Analyst’s mean target price for uniQure N.V. (NASDAQ:QURE) is $30.10 while analysts mean recommendation is 1.60. QURE EPS growth this year is -49.60%.

👍️0
redsox17 redsox17 8 years ago
I see over 100 % upside from here. Go QURE
👍️0
Panzer Panzer 8 years ago
Not sure but panzers got blasted. Data in December so will average down here and stay put
👍️0
jaytea jaytea 8 years ago
WTF happened here today?
👍️0
Panzer Panzer 8 years ago
Adding all under 9s
👍️0
Panzer Panzer 8 years ago
QURE data will show in PPS hang on tight
👍️0
Panzer Panzer 8 years ago
QURE will double here into December
👍️0
Panzer Panzer 8 years ago
Laaaaaid back QURE love it
👍️0
Panzer Panzer 8 years ago
End of summer QURE prediction will happen
👍️0
Panzer Panzer 8 years ago
QURE run to 12+ on it watch
👍️0
Panzer Panzer 8 years ago
Panzer nailing biotechs sniper
👍️0

Your Recent History

Delayed Upgrade Clock